What Is Semax?
Semax is a synthetic heptapeptide — the sequence Met-Glu-His-Phe-Pro-Gly-Pro — derived from the adrenocorticotropic hormone (ACTH) fragment 4–7 with a C-terminal proline-glycine-proline (PGP) extension that increases its stability in biological systems. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has a substantial research history in Russian clinical settings, including approved use for cerebral ischemia treatment.
Semax is one of the most extensively studied nootropic peptides in the literature, with documented effects on neurotrophic factor expression, dopaminergic and serotonergic signaling, and neuroprotection in ischemic injury models.
Semax is one of seven peptides scheduled for PCAC evaluation at the FDA's July 23–24 hearing. It is on the Day 2 agenda, being reviewed in the context of cerebral ischemia, migraine, and trigeminal neuralgia research applications. See the full regulatory timeline.
Mechanisms of Action
BDNF & NGF Upregulation
Semax's most well-documented effect is the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Both are critical for neuronal survival, synaptic plasticity, and long-term potentiation (LTP) — the cellular basis of learning and memory. BDNF upregulation is a key target in research on cognitive decline, depression, and neurodegeneration.
Dopaminergic & Serotonergic Modulation
Semax influences both the dopaminergic and serotonergic systems — which underlie motivation, working memory, mood regulation, and executive function. Animal studies show enhanced dopamine turnover in prefrontal cortex regions associated with cognitive processing.
Neuroprotection in Ischemia Models
The most clinically-oriented research on Semax focuses on cerebral ischemia — reduced blood flow to the brain. Multiple studies in rodent stroke models demonstrate reduced infarct volume, improved neurological outcomes, and accelerated recovery. This is the basis for its approved use in Russian medicine for ischemic stroke therapy.
HIF-1 Pathway Activation
Semax activates hypoxia-inducible factor 1 (HIF-1), a transcription factor that regulates cellular responses to low oxygen. This pathway is relevant to both ischemia protection and general cellular resilience under oxidative stress conditions.
Research Specifications
| Property | Value |
|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) |
| Molecular weight | ~813.9 Da |
| ACTH origin | Fragment 4–7 with PGP C-terminal extension |
| Common formulations | Lyophilized powder; nasal spray |
| Storage | Refrigerated 2–8°C, protect from light |
| FDA 2026 status | Removed from Category 2 · PCAC July 24 evaluation |
Semax vs. Selank
Semax and Selank are the two most commonly co-discussed cognitive research peptides. They have distinct mechanisms and complement each other in research protocols:
| Property | Semax | Selank |
|---|---|---|
| Primary effect | Cognitive enhancement, neuroprotection | Anxiolytic, anti-stress |
| Key mechanism | BDNF/NGF upregulation, dopaminergic | GABAergic, enkephalin stabilization |
| PCAC July 2026 | Yes — Day 2, July 24 | No — separate review TBD |
| Clinical history | Approved in Russia for cerebral ischemia | Used clinically in Russia for anxiety |